Literature DB >> 1519249

Pioneers of anti-venomous serotherapy: Dr Vital Brazil (1865-1950).

B J Hawgood.   

Abstract

Dr Vital Brazil was a great humanitarian and pioneer of medical science. His main work arose from his concern with poisonous snakebite accidents to labourers working the land. Vital Brazil estimated that, at the beginning of this century, deaths due to crotaline snakebites in the State of São Paulo, Brazil, were nearly 3000 per year, representing a mortality rate of about 25%, the majority being due to bothropic envenomation. After reading a report of Calmette's anti-Naja serum, Vital Brazil raised monovalent serum against the venom of Bothrops jararaca and the venom of Crotalus durissus terrificus. In 1989 this led to the first demonstration of the specificity of anti-venomous serum and later, the first production of polyvalent serum for therapeutic use. As Director of the newly founded Institute Butantan in São Paulo, Vital Brazil was actively engaged in every aspect of serotherapeutic treatment. This included organizing a unique system of exchanging anti-ophidic serum for snakes as well as a wide-ranging teaching programme. His many outstanding contributions to the fields of immunology, public health, toxinology and herpetology required not only a very high level of observational, deductive and practical ability but also an unswerving vision and sense of duty; this was allied to great administrative skill and exceptional energy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1519249     DOI: 10.1016/0041-0101(92)90851-u

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  From ETOH to FAB: the medicalization of therapy for pit viper envenomation.

Authors:  C S Kitchens
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 2.  History of Envenoming Therapy and Current Perspectives.

Authors:  Manuela B Pucca; Felipe A Cerni; Rahel Janke; Erick Bermúdez-Méndez; Line Ledsgaard; José E Barbosa; Andreas H Laustsen
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 3.  Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs.

Authors:  Luiza Helena Gremski; Fernando Hitomi Matsubara; Nayanne Louise Costacurta Polli; Bruno Cesar Antunes; Pedro Henrique de Caires Schluga; Hanna Câmara da Justa; João Carlos Minozzo; Ana Carolina Martins Wille; Andrea Senff-Ribeiro; Silvio Sanches Veiga
Journal:  Front Mol Biosci       Date:  2021-06-17

4.  The Butantan Institute: history and future perspectives.

Authors:  Marcelo De Franco; Jorge Kalil
Journal:  PLoS Negl Trop Dis       Date:  2014-07-03

Review 5.  Amplification of Snake Venom Toxicity by Endogenous Signaling Pathways.

Authors:  Philip E Bickler
Journal:  Toxins (Basel)       Date:  2020-01-22       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.